REFERENCES OF INTEREST

Vaezi A, Healy T, Ebrahimi G et al. Phage therapy: breathing new tactics into lower respiratory tract infection treatments. Eur Respir Rev. 2024;33(172):240029.

Murray TS, Stanley G, Koff JL. Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis. Infect Dis Clin North Am.2024;38(1):149-162.

Law N, Logan C, Yung G et al. Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient. Infection. 2019;47(4):665-668.

Hoyle N, Zhvaniya P, Balarjishvili N et al. Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report. Res Microbiol. 2018;169(9):540-542.

Bradley JS, Hajama H, Akong K et al. Bacteriophage Therapy of Multidrug-resistant Achromobacter in an 11-Year-old Boy with Cystic Fibrosis Assessed by Metagenome Analysis. Pediatr Infect Dis J. 2023;42(9):754-759.

Hatfull GF. Phage Therapy for Nontuberculous Mycobacteria: Challenges and Opportunities. Pulm Ther. 2023;9(1):91-107. Nick JA, Dedrick RM, Gray AL et al. Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell. 2022. 26;185(11):1860-1874.

Dedrick RM, Guerrero-Bustamante CA, Garlena RA et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019;25(5):730-733.

Haidar G, Chan BK, Cho ST et al. Phage therapy in a lung transplant recipient with cystic fibrosis infected with multidrug-resistant Burkholderia multivorans. Transpl Infect Dis. 2023;25(2):e14041.

Rappo U, Cohen A, Kario E et al. Nebulized Phage Therapy for Patients with Cystic Fibrosis with Chronic Pseudomonas aeruginosa Pulmonary Infection: A Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. Open Forum Infect Dis. 2023;10 (Suppl 2)

Hwang W, Yong JH, Lenneman BR, Yonker LM. Phage-Based Approaches to Chronic Pseudomonas aeruginosa Lung Infection in Cystic Fibrosis. Antibiotics (Basel) 2026:15(2)

Jafari A, Elikaei A, Gowdini E, Ali AA, Meidaninikjeh S. Isolation, characterization, and genomic analysis of novel bacteriophage AEV23 against multidrug-resistant Klebsiella pneumoniae isolated from Cystic Fibrosis patients. BMC Microbiol; 2026 (1):135

Yerushalmy O, Korn AM, Yao G, Hazan R, Gonzalez CF, Gill JJ, Kalikin LM, Spilker T, Caverly LJ, Bumford AA, Wallace NR, Aslam S, Nir-Paz R, Van Tyne D, LiPuma JJ. Intra-individual diversity of bacteriophage susceptibility in Burkholderia cultured from cystic fibrosis sputum.  J Cyst Fibros 2025; 24(5):876-878

Cafora M, Dobi D, William JNG, Forti F, Belleri L, Loberto N, Bassi R, Carbone S, Locati M, Aureli M, Briani F, Pistocchi A. Anti-inflammatory activity of Pseudomonas aeruginosa DEV phage in cystic fibrosis models. J Cyst Fibros 2025; 24(5):867-875.

Nick JA, Martiniano SL, Lovell VK, Vestal B, Poch K, Caceres SM, Rysavy NM, de Moura VC, Gilick JJ, Malcolm KC, Pacheco J, Amin AG, Chatterjee D, Daley CL, Kasperbauer S, Gross JE, Armantrout E, Cohen KA, Keck A, Vandalfsen JM, Magaret AS, Midamba N, Chapdu C, Gao A, Hill JE, Freeman KG, Cristinziano M, Guerrero C, Jacobs-Sera D, Lauer MJ, Viland M, Hatfull GF. Trial design of bacteriophage therapy for nontuberculous mycobacteria pulmonary disease in cystic fibrosis: The POSTSTAMP study. J Cyst Fibros 2025; 24(4):684-690.

Weiner I, Kahan-Hanum M, Buchstab N, Zelcbuch L, Navok S, Sherman I, Nicenboim J, Axelrod T, Berko-Ashur D, Olshina M, Mordoch R, Jablonska J, Gera-Inbar T, Vainberg-Slutskin I, Blumenfeld B, Sberro-Livnat H, Moses A, Nevenzel H, Levy-Saar I, Gold J, Goldberg M, Tchernorudsky N, Ben-Yishay N, Cohen T, Kario E, Levovich I, Safonov R, Tzur Y, Zarchin Y, Lev V, Elharar Y, Safyon-Gartman E, Gahali-Sass I, Puttagunta S, Ussery X, Vilchez R, Rappo U, Zak N, Golembo M, Cohen A, Koff J, Kerem E, Sorek R, Bassan M. Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial. Nat Commun 2025 ;16(1):5579

Chan BK, Stanley GL, Kortright KE, Vill AC, Modak M, Ott IM, Sun Y, Wurstle S, Grun CN, Kazmierczak BI, Rajagopalan G, Harris ZM, Britto CJ, Stewart J, Talwalkar JS, Appell CR, Chaudary N, Jagpal SK, Jain R, Kanu A, Quon BS, Reynolds JM, Teneback CC, Mai QA, Shabanova V, Turner PE, Koff JL. Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis. Nat Med 2025;31(5):1494-1501

Kurt KC, Kurt H, Tokuc E, Ozbey D, Arabaci DN, Aydin S, Gonullu N, Skurnik M, Tokman HB. Isolation and characterization of new lytic bacteriophage PSA-KC1 against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Sci. rep. 2025; 15(1):6551.

Singh J, Lynch S, Iredell J, Selvadurai H. Safety and tolerability of bronchoscopic and nebulised administration of bacteriophage. Virus Res 2024; 348:199442

Cocorullo M, Stelitano G, Chiarelli LR. Phage Therapy: An Alternative Approach to Combating Multidrug-Resistant Bacterial Infections in Cystic Fibrosis. Int. J Mol. Sci : 2024; 25(15)

Wang Z, De Soir S, Glorieux A, Merabishvili M, Knoop C, De Vos D, Pirnay JP, Van Bambeke F. Bacteriophages as potential antibiotic potentiators in cystic fibrosis: A new model to study the combination of antibiotics with a bacteriophage cocktail targeting dual species biofilms of Staphylococcus aureus and Pseudomonas aeruginosa. Int J Antimicrob Agents ; 2024 ; 64(3):107276.

Murray TS, Stanley G, Koff JL. Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis.]  Infect Dis Clin North Am. 2024;38(1):149-162

Schmalstig AA, Wiggins A, Badillo D, Wetzel KS, Hatfull GF, Braunstein M. Bacteriophage infection and killing of intracellular Mycobacterium abscessus. mBio. 2024;15(1):e0292423.

Singh J, Yeoh E, Fitzgerald DA, Selvadurai H. A systematic review on the use of bacteriophage in treating Staphylococcus aureus and Pseudomonas aeruginosa infections in cystic fibrosis.]  Paediatr Respir Rev 2023 ; 48:3-9